Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
6978 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$1.50 - HK$6.15
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.27M
Market Cap
HK$1.90B
Enterprise ValueHK$2.26B
Total Cash (Recent Filing)¥52.16M
Total Debt (Recent Filing)¥457.17M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Aug 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding514,584,000
10 Day Avg. Volume1,451,800
30 Day Avg. Volume1,273,233
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Immunotech Biopharm Ltd News
PremiumCompany Announcements
Immunotech Biopharm Ltd Postpones Board Meeting to Finalize Annual Results
PremiumCompany Announcements
Immunotech Biopharm Ltd Schedules Board Meeting for Annual Results
PremiumCompany Announcements
Immunotech Biopharm Prepares Conditional Approval Submission for EAL®
PremiumCompany Announcements
Immunotech Biopharm Transfers Convertible Bonds to Tibet Jiaze
PremiumCompany Announcements
Immunotech Biopharm’s CAR-T-19 Gains Breakthrough Status
PremiumCompany Announcements
Immunotech Biopharm’s Strategic Move in Gene Therapy
PremiumCompany Announcements
Immunotech Biopharm Announces Leadership ChangesPremiumCompany Announcements
Immunotech Biopharm Reduces Losses, Advances R&D---
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$1.50 and its highest was HK$6.15 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$1.90B.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Aug 22, 2025 which is in 145 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Aug 23, 2024. The company reported -HK$0.195 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.195.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 514,584,000 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.195 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.949%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
---
Immunotech Biopharm Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.07%
12-Months-Change
Fundamentals
Return on Equity
-131.58%
Trailing 12-Months
Asset Growth
-30.93%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
---
Technical Analysis
Wuxi Biologics (Cayman)
―
Genor Biopharma Holdings Limited
―
Akeso, Inc.
―
Viva Biotech Holdings
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
---